Drug
Teclistamab-cqyv
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Cytokine Release Syndrome | 508 | 271.1 | 356.3 | signal |
| 2 | Plasma Cell Myeloma | 123 | 31.2 | 33.1 | signal |
| 3 | Cytopenia | 32 | 26.6 | 27.0 | signal |
| 4 | Adverse Reaction | 27 | 20.2 | 20.4 | signal |
| 5 | Neurotoxicity | 32 | 18.3 | 18.5 | signal |
| 6 | Respiratory Tract Infection | 36 | 13.7 | 14.0 | signal |
| 7 | Clostridium Difficile Colitis | 12 | 11.2 | 11.3 | signal |
| 8 | Cytomegalovirus Infection | 17 | 10.1 | 10.2 | signal |
| 9 | Bacteraemia | 12 | 10.1 | 10.1 | signal |
| 10 | Covid-19 Pneumonia | 11 | 9.2 | 9.2 | signal |
| 11 | Pneumocystis Jirovecii Pneumonia | 9 | 8.9 | 9.0 | signal |
| 12 | Infection | 112 | 7.7 | 8.1 | signal |
| 13 | Urosepsis | 7 | 7.5 | 7.5 | signal |
| 14 | Colitis | 26 | 6.8 | 6.9 | signal |
| 15 | Neutropenia | 93 | 6.8 | 7.1 | signal |
| 16 | Transfusion | 7 | 6.6 | 6.6 | signal |
| 17 | Hypercalcaemia | 8 | 6.4 | 6.4 | signal |
| 18 | Hospice Care | 6 | 6.0 | 6.0 | signal |
| 19 | Product Prescribing Issue | 12 | 5.8 | 5.9 | signal |
| 20 | Septic Shock | 25 | 5.7 | 5.8 | signal |
| 21 | Full Blood Count Abnormal | 6 | 5.6 | 5.6 | signal |
| 22 | Injection Site Rash | 17 | 5.5 | 5.6 | signal |
| 23 | Status Epilepticus | 6 | 5.2 | 5.3 | signal |
| 24 | Lymphopenia | 7 | 4.9 | 4.9 | signal |
| 25 | Immunodeficiency | 7 | 4.7 | 4.7 | signal |
| 26 | Clostridium Difficile Infection | 10 | 4.6 | 4.6 | signal |
| 27 | Covid-19 | 79 | 4.4 | 4.6 | signal |
| 28 | Neutrophil Count Decreased | 18 | 4.4 | 4.4 | signal |
| 29 | Bone Pain | 25 | 4.2 | 4.3 | signal |
| 30 | Myelodysplastic Syndrome | 6 | 4.1 | 4.1 | signal |
| 31 | Thrombotic Microangiopathy | 4 | 4.1 | 4.1 | signal |
| 32 | Decreased Immune Responsiveness | 4 | 4.1 | 4.1 | signal |
| 33 | Product Preparation Error | 8 | 3.8 | 3.8 | signal |
| 34 | Acute Myeloid Leukaemia | 6 | 3.8 | 3.8 | signal |
| 35 | Injection Site Reaction | 24 | 3.5 | 3.5 | signal |
| 36 | Adverse Event | 30 | 3.2 | 3.3 | signal |
| 37 | Myelosuppression | 11 | 3.2 | 3.2 | signal |
| 38 | Toxic Skin Eruption | 3 | 2.9 | 2.9 | no signal |
| 39 | Uveitis | 4 | 2.9 | 2.9 | no signal |
| 40 | Hepatic Cytolysis | 3 | 2.4 | 2.4 | no signal |
| 41 | Injection Site Pruritus | 12 | 1.8 | 1.8 | no signal |
| 42 | Injection Site Erythema | 19 | 1.5 | 1.5 | no signal |